Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating
© MT Newswires 2022
All news about PROTAGONIST THERAPEUTICS, INC. |
|
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2500 Growth Index | CI |
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000 Growth Index | CI |
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Microcap Value Index | CI |
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Small Cap Comp Value Index | CI |
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 2000 Value Index | CI |
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell Small Cap Comp Growth In.. | CI |
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2000 Growth Index | CI |
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 3000 Value Index | CI |
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 3000E Value Index | CI |
06/24 | PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000E Growth Index | CI |
|
|
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC. |
|
|
| |
|
Sales 2022 |
31,9 M
-
-
|
Net income 2022 |
-157 M
-
-
|
Net cash 2022 |
174 M
-
-
|
P/E ratio 2022 |
-2,67x |
Yield 2022 |
- |
|
Capitalization |
411 M
411 M
-
|
EV / Sales 2022 |
7,43x |
EV / Sales 2023 |
29,8x |
Nbr of Employees |
122 |
Free-Float |
98,6% |
|
Chart PROTAGONIST THERAPEUTICS, INC. |
|
Duration :
Period :
|
 |
|
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
| Short Term | Mid-Term | Long Term | Trends | Bullish | Bearish | Bearish |
Income Statement Evolution
|
Mean consensus |
BUY |
Number of Analysts |
6 |
Last Close Price |
8,45 $ |
Average target price |
40,00 $ |
Spread / Average Target |
373% |
|